Gilead Sciences Announces First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Gilead Sciences (GILD) PT Lowered to $118 at UBS
April 29, 2016 8:27 AM EDTUBS analyst Marc Goodman lowered his price target on Gilead Sciences (NASDAQ: GILD) to $118.00 (from $130.00) following Q1 results but maintained a Buy rating.
Goddman commented, "We have lowered our HCV sales estimates to reflect lower ASPs (higher rebates to defend share from Merck's... More
Gilead Sciences (GILD) Needs M&A to Fill the Gap Following HCV Miss - BMO Capital
April 29, 2016 7:40 AM EDTBMO Capital analyst M. Ian Somaiya lowered his price target on Gilead Sciences (NASDAQ: GILD) to $97.00 (from $102.00) following the HCV miss. The firm maintained a Market Perform rating, saying it increases the need for pipeline.
Somaiya commented, "Gilead reported 1Q16 EPS... More
Baird Maintains Bullish View on Gilead Sciences (GILD) Despite Top-Line Miss on U.S. Hep C Sales
April 29, 2016 7:30 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $135 on Gilead Sciences (NASDAQ: GILD) despite a top-line miss driven by weaker U.S. Hep C sales.
Skorney commented, "U.S. Hep C sales came in several hundred million dollars short of expectations.... More
Maxim Group Downgrades Gilead Sciences (GILD) to Hold
April 29, 2016 7:06 AM EDTMaxim Group downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Hold.
Analyst Jason Kolbert highlighted:
Gilead reported quarterly results with total top-line revenues of $7.6B missing consensus of $7.7B by a hair. Non-GAAP quarterly net income was $4.3B or $3.03 per diluted share. The company ended the period with $21.3B in cash and $22B in debt.HCV revenues continue to drive Gilead but tough comps, the laws of growth (for big numbers), and... MoreGilead Sciences (GILD) PT Trimmed to $123 at Leerink Partners
April 29, 2016 6:50 AM EDTLeerink Partners analyst Geoffrey Porges trimmed his price target on Gilead Sciences (NASDAQ: GILD) to $123.00 (from $127.00) following disappointing Q1 results but maintained an Outperform rating.
Porges commented, "The weakness came in the HCV products, where revenue slid in the US market in the face of... More
Gilead Sciences (GILD) Misses Q1 EPS by 10c
April 28, 2016 4:05 PM EDTGilead Sciences (NASDAQ: GILD) reported Q1 EPS of $3.03, $0.10 worse than the analyst estimate of $3.13. Revenue for the quarter came in at $7.8 billion versus the consensus estimate of $8.08 billion. Gilead Sciences reaffirmed FY2016 guidance.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
... More